# Robert C. Doebele

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-c-doebele/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,118 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 74 |
| i10-index | 196 |
| Last Known Institution | The Medical Center of Aurora |
| OpenAlex ID | https://openalex.org/A5034705456 |
| ORCID iD | https://orcid.org/0000-0001-6728-6857 |
| Works | 534 |

## Researcher papers

Showing 12 of 15.

- [Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children](https://scholariq.org/papers/efficacy-of-larotrectinib-in-i-trk-i-fusion-positive-cancers-in-adults-and/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study](https://scholariq.org/papers/local-consolidative-therapy-vs-maintenance-therapy-or-observation-for-patients/)
- [Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study](https://scholariq.org/papers/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for/)
- [Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis](https://scholariq.org/papers/effect-of-crizotinib-on-overall-survival-in-patients-with-advanced-non-small/)
- [Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-multitargeted-pan-trk-ros1-and-alk/)
- [Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing](https://scholariq.org/papers/therapy-induced-evolution-of-human-lung-cancer-revealed-by-single-cell-rna/)
- [Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-ros1-fusion-positive-non-small-cell-lung-cancer-integrated/)
- [Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study](https://scholariq.org/papers/pralsetinib-for-ret-fusion-positive-non-small-cell-lung-cancer-arrow-a-multi/)
- [Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry](https://scholariq.org/papers/targeting-ret-in-patients-with-i-ret-i-rearranged-lung-cancers-results-from-the/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [The Medical Center of Aurora](https://scholariq.org/institutions/the-medical-center-of-aurora/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.